Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data

dc.date.accessioned	2023-03-06T07:31:37Z
dc.date.available	2023-03-06T07:31:37Z
dc.date.issued	2021
dc.identifier.citation	Clin Exp Rheumatol. 2021 Jul-Aug;39(4):852-858. doi: 10.55563/clinexprheumatol/jhpymv. Epub 2020 Sep 4.
dc.identifier.uri	https://hdl.handle.net/20.500.12619/99820
dc.relation.isversionof	10.55563/clinexprheumatol/jhpymv
dc.relation.isversionof	10.55563/clinexprheumatol/jhpymv
dc.title	Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data
dc.relation.journal	Clin Exp Rheumatol
dc.identifier.doi	10.55563/clinexprheumatol/jhpymv
dc.contributor.author	Kimyon G
dc.contributor.author	Kimyon G
dc.contributor.author	Kalyoncu U
dc.contributor.author	Kiraz S
dc.contributor.author	Bes C
dc.contributor.author	Coşkun N
dc.contributor.author	Yağiz B
dc.contributor.author	Küçükşahin O